← Leaderboards
Michael A Barry
Baylor College Of Medicine
$17,628,136
Attributed
$18,786,773
Total exposure
18
Grants
13
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$18,786,773 · 18
By mechanism
R01$15,793,572 · 9
R56$1,936,581 · 3
R21$1,006,803 · 3
P41$49,817 · 3
Top collaborators
- Jagannadha K Sastry3 shared
Most similar at Baylor College Of Medicine
Same institution · by research overlap
- Innocent N Mbawuike$2,138,193
- Troy R Torgerson$5,841,511
- Dov Kadmon$403,249
- Ivan Kingyue Chinn$1,057,680
Others in their field
Top investigators on “Immune Response”
- Lawrence Corey · Fred Hutchinson Cancer Center$680,290,567
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$542,695,345
- Barton F Haynes · Duke University$456,664,915
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$309,708,725
- Peter B. Gilbert · Fred Hutchinson Cancer Center$192,329,665
Research focus
Immune ResponseVirusCellsAdenovirusesResponseVaccinesInfectionMediatingImmunizationGenesImmuneProteinsVaccinationViralFutureHiv-1BaseSerotypingSurfaceAntibodiesMacaca MulattaHiv VaccineMucosal Immune ResponsesVector
Grant awards (51)
Ebola Virus Life Cycle Modeling In Vivo$441,100
R21 · FY2025 · AI · contact PI
Pushing HIV-1 Vaccine Protection to the Mucosal Barrier$745,752
R56 · FY2024 · AI · contact PI
Mechanisms of Ebola virus-mediated inflammatory activation linked to pathogenesis$692,822
R01 · FY2023 · AI · contact PI
Shielding Replicating Single-cycle Vaccines against SARS-CoV-2$470,627
R56 · FY2023 · AI · contact PI
Mechanisms of Ebola virus-mediated inflammatory activation linked to pathogenesis$687,322
R01 · FY2022 · AI · contact PI
Mechanisms of Ebola virus-mediated inflammatory activation linked to pathogenesis$696,742
R01 · FY2021 · AI · contact PI
Vaccine Synergy through Synchronous Delivery$741,448
R01 · FY2020 · AI · contact PI
Mechanisms of Ebola virus-mediated inflammatory activation linked to pathogenesis$663,887
R01 · FY2020 · AI · contact PI
Vaccine Synergy through Synchronous Delivery$798,766
R01 · FY2019 · AI · contact PI
Vaccine Synergy through Synchronous Delivery$777,061
R01 · FY2018 · AI · contact PI
Mucosal Single-Cycle Vaccines against Zika Virus$238,500
R21 · FY2018 · AI · contact PI
Mucosal Single-Cycle Vaccines against Zika Virus$198,750
R21 · FY2017 · AI · contact PI
Immunoevasive Mucosal Vaccines Against HIV-1$780,426
R01 · FY2016 · AI · contact PI
Immunoevasive Mucosal Vaccines Against HIV-1$776,040
R01 · FY2015 · AI · contact PI
Immunoevasive Mucosal Vaccines Against HIV-1$48,562
R01 · FY2015 · AI · contact PI
Immunoevasive Mucosal Vaccines Against HIV-1$782,400
R01 · FY2014 · AI · contact PI
Improving the Pharmacology of Oncolytic Adenovirus$295,003
R01 · FY2014 · CA · contact PI
Immunoevasive Mucosal Vaccines Against HIV-1$302,618
R01 · FY2013 · AI · contact PI
Improving the Pharmacology of Oncolytic Adenovirus$285,880
R01 · FY2013 · CA · contact PI
Immunoevasive Mucosal Vaccines Against HIV-1$336,685
R01 · FY2012 · AI · contact PI
Improving the Pharmacology of Oncolytic Adenovirus$304,127
R01 · FY2012 · CA · contact PI
Mucosal Reovirus-Adenovirus Vaccines Against HIV-1$370,233
R01 · FY2011 · AI · contact PI
Improving the Pharmacology of Oncolytic Adenovirus$304,127
R01 · FY2011 · CA · contact PI
Mucosal Reovirus-Adenovirus Vaccines Against HIV-1$373,973
R01 · FY2010 · AI · contact PI
Improving the Pharmacology of Oncolytic Adenovirus$313,533
R01 · FY2010 · CA · contact PI
Mucosal Helper-dependent Adenovirus Vaccines Against HIV$720,202
R56 · FY2009 · AI · contact PI
Mucosal Reovirus-Adenovirus Vaccines Against HIV-1$377,750
R01 · FY2009 · AI · contact PI
Mucosal Reovirus-Adenovirus Vaccines Against HIV-1$377,750
R01 · FY2008 · AI · contact PI
Mucosal Helper-dependent Adenovirus Vaccines Against HIV-1$271,659
R01 · FY2008 · AI · contact PI
Mucosal Helper-dependent Adenovirus Vaccines Against HIV-1$280,661
R01 · FY2007 · AI · contact PI
CELL-TARGETTING ADENOVIRAL VECTORS$16,289
P41 · FY2007 · RR · contact PI
Mucosal Helper-dependent Adenovirus Vaccines Against HIV-1$217,989
R01 · FY2006 · AI · contact PI
Mucosal Helper-dependent Adenovirus Vaccines Against HIV-1$72,015
R01 · FY2006 · AI · contact PI
CELL-TARGETTING ADENOVIRAL VECTORS$15,059
P41 · FY2006 · RR · contact PI
Cell Targeting Ligands and Vectors for CLL$267,890
R01 · FY2005 · CA
Mucosal Helper-dependent Adenovirus Vaccines Against HIV-1$255,000
R01 · FY2005 · AI
CELL-TARGETING ADENOVIRAL VECTORS$18,469
P41 · FY2005 · RR
Genetic Vaccines Against HIV Mutants$376,250
R01 · FY2004 · AI
Cell Targeting Ligands and Vectors for CLL$267,890
R01 · FY2004 · CA
Cell Targeting Ligands and Vectors for CLL$48,062
R01 · FY2004 · CA
Genetic Vaccines Against HIV Mutants$376,250
R01 · FY2003 · AI
PHENOTYPE SCREENS FOR BONE MARROW FAILURE$373,750
R01 · FY2003 · HL
Cell Targeting Ligands and Vectors for CLL$267,890
R01 · FY2003 · CA
Genetic Vaccines Against HIV Mutants$376,250
R01 · FY2002 · AI
PHENOTYPE SCREENS FOR BONE MARROW FAILURE$373,750
R01 · FY2002 · HL
Cell Targeting Ligands and Vectors for CLL$267,890
R01 · FY2002 · CA
PHENOTYPE SCREENS FOR BONE MARROW FAILURE$373,750
R01 · FY2001 · HL
F MRI STUDY OF TASTE CORTEX USING FOCAL STIMULI$47,450
R21 · FY2001 · DC
F MRI STUDY OF TASTE CORTEX USING FOCAL STIMULI$11,353
R21 · FY2001 · DC
GENETIC VACCINES AGAINST HIV MUTANTS$239,471
R01 · FY2000 · AI
F MRI STUDY OF TASTE CORTEX USING FOCAL STIMULI$69,650
R21 · FY2000 · DC